Resultado da Busca
Janet Woodcock (born August 29, 1948) is an American physician serving as Principal Deputy Commissioner of Food and Drugs, having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA).
17 de fev. de 2022 · Janet Woodcock is the FDA’s Principal Deputy Commissioner and the former Acting Commissioner of Food and Drugs. She has led the agency’s drug evaluation and approval, biologics research, and COVID-19 response, and received many honors for her public health career.
- Principal Deputy Commissioner
- Office of The Commissioner
16 de nov. de 2023 · WASHINGTON, Nov 16 (Reuters) - U.S. Food and Drug Administration (FDA) Principal Deputy Commissioner Dr. Janet Woodcock, who led the regulator during the height of the COVID-19 pandemic as...
16 de nov. de 2023 · US Food and Drug Administration Deputy Commissioner Janet Woodcock will retire next year after nearly four decades at the regulator that were marked by controversy over support for unproven...
17 de nov. de 2023 · The longtime regulator, who led the agency's drug evaluation center and Covid-19 response, plans to leave in early 2024, FDA Commissioner Robert Califf announced. Woodcock is a legend in public health and has made enduring improvements in FDA operations, according to former and current officials.
16 de nov. de 2023 · Senior Reporter. Fiona Rutherford. Bloomberg News. US Food and Drug Administration Deputy Commissioner Janet Woodcock will retire next year after nearly four decades at the regulator that were marked by controversy over support for unproven medications for rare, serious conditions. Woodcock confirmed the news in an email.
30 de jan. de 2024 · Janet Woodcock, the FDA's principal deputy commissioner, reflects on her more than 30 years at the agency and hints at what's next. She oversaw hundreds of drug reviews, faced Covid-19 challenges and a reorganization plan.
